Get started
Author

Ayodele O. Ogunkoya

Observed names: Ogunkoya Ayodele, Ogunkoya, A.O., Ogunkoya, Ayodele, Ogunkoya, Ayodele O.
ORCID: 0009-0006-8249-1377
Observed ORCID: 0009-0006-8249-1377
OpenAlex ID: A5044585220
Chemical Protein Synthesis by Chemoselective α‐Ketoacid–Hydroxylamine (KAHA) Ligations with 5‐Oxaproline
2012 · Vijaya R. Pattabiraman, Ayodele O. Ogunkoya, et al. · Angewandte Chemie International Edition · 130
Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody–Drug Conjugates
2021 · Stepan Chuprakov, Ayodele O. Ogunkoya, et al. · Bioconjugate Chemistry · 86
Sequential α‐Ketoacid‐Hydroxylamine (KAHA) Ligations: Synthesis of C‐Terminal Variants of the Modifier Protein UFM1
2012 · Ayodele O. Ogunkoya, Vijaya R. Pattabiraman, et al. · Angewandte Chemie International Edition · 74
Chemical Protein Synthesis by Chemoselective α‐Ketoacid–Hydroxylamine (KAHA) Ligations with 5‐Oxaproline
2012 · Vijaya R. Pattabiraman, Ayodele O. Ogunkoya, et al. · Angewandte Chemie · 30
Sequentielle α‐Ketosäurehydroxylamin(KAHA)‐Ligationen: Synthese C‐terminaler Varianten des Modifikationsproteins UFM1
2012 · Ayodele O. Ogunkoya, Vijaya R. Pattabiraman, et al. · Angewandte Chemie · 14
A Novel HER2-targeted Antibody–drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels
2020 · Robyn M. Barfield, Yun Cheol Kim, et al. · Molecular Cancer Therapeutics · 13
PDF
Aspartic Acid Forming α-Ketoacid–Hydroxylamine (KAHA) Ligations with (S)-4,4-Difluoro-5-oxaproline
2019 · Simon Baldauf, Ayodele O. Ogunkoya, et al. · The Journal of Organic Chemistry · 9
Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al. · Molecular Cancer Therapeutics · 4
PDF
Amide‐Forming Ligation Reactions
2019 · Vijaya R. Pattabiraman, Ayodele O. Ogunkoya, et al. · Organic reactions · 3
Titelbild: Chemical Protein Synthesis by Chemoselective α‐Ketoacid–Hydroxylamine (KAHA) Ligations with 5‐Oxaproline (Angew. Chem. 21/2012)
2012 · Vijaya R. Pattabiraman, Ayodele O. Ogunkoya, et al. · Angewandte Chemie · 2
Corrigendum: Chemical Protein Synthesis by Chemoselective α‐Ketoacid–Hydroxylamine (KAHA) Ligations with 5‐Oxaproline
2014 · Vijaya R. Pattabiraman, Ayodele O. Ogunkoya, et al. · Angewandte Chemie International Edition · 1
PDF
Data from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure 2 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure 3 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure 4 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S3 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure 5 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S2 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S1 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S4 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table 1 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S5 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S4 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S1 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S6 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Works count: 47
Citation count: 366
H-index: 7
I10-index: 6
Year
Topic
Type